MediPharm Labs Announces Participation at Upcoming BMO & TMX Hemp & Medical Cannabis Conference in London, UK
October 07 2019 - 7:15AM
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ)
(“MediPharm Labs” or the “Company”) a global leader in specialized,
research-driven cannabis extraction, distillation, purification and
cannabinoid isolation, is pleased to announce its participation at
the BMO & TMX Hemp & Medical Cannabis Conference in London,
UK on October 16, 2019.
Pat McCutcheon, CEO of MediPharm Labs, will
participate on a panel discussion that will provide an update on
key medical cannabis markets in Europe. MediPharm Labs will
be presenting alongside management representatives from Aurora
Cannabis Inc. and Canopy Growth Corp. The Company will also
be available for pre-scheduled one-on-one meetings during the
conference.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in
the production of purified, pharmaceutical-like cannabis oil and
concentrates and advanced derivative products utilizing a Good
Manufacturing Practices designed facility and ISO standard built
clean rooms. MediPharm Labs has invested in an expert, research
driven team, state-of-the-art technology, downstream purification
methodologies and purpose-built facilities with five primary
extraction lines having 300,000 kg of annual processing capacity to
deliver pure, trusted and precisely-dosed cannabis products for its
customers. Through its wholesale, white label and tolling
platforms, they formulate, process, package and distribute cannabis
extracts and advanced cannabinoid-based products to domestic and
international markets. As a global leader, the Company also
completed commercial exports to Australia and is nearing completion
of its Australian extraction facility expected in 2019 with 75,000
kg of annual processing capacity.
For more information:Laura
Lepore, VP, Investor Relations Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION:This news release contains
“forward-looking information” and “forward-looking statements”
(collectively, “forward-looking statements”) within the meaning of
the applicable Canadian securities legislation. All statements,
other than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that involves
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or
performance (often but not always using phrases such as “expects”,
or “does not expect”, “is expected”, “anticipates” or “does not
anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. In this news release, forward-looking
statements relate to, among other things, the completion of
MediPharm Labs’ Australian facility and timing thereof, and
expected processing capacity of the Australian facility.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm Labs to obtain
adequate financing; the delay or failure to receive regulatory
approvals; and other factors discussed in MediPharm Labs’ filings,
available on the SEDAR website at www.sedar.com. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, MediPharm Labs assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change.
VIVO Cannabis (TSX:LABS)
Historical Stock Chart
From Aug 2024 to Sep 2024
VIVO Cannabis (TSX:LABS)
Historical Stock Chart
From Sep 2023 to Sep 2024